US Biotech Firm Chooses Hong Kong for Initial Listing

A U.S. biotech firm has opted to list in Hong Kong first, bypassing Wall Street, as global biotech companies are increasingly drawn to the city's growing investor base and its proximity to Chinese pharmaceutical partners.